Phase 2 ACUITY data for Privosegtor (OCS-05) in acute optic neuritis show improvements in low-contrast visual acuity along with anatomical preservation of retinal ganglion cells in a randomized, double-masked, placebo-controlled study. Separately, expanded analyses from Stage 1 of the DIAMOND program for OCS-01 eye drops in diabetic macular edema (DME) indicate consistent 12-week efficacy and safety across subgroups divided by lens status and prior treatment exposure.
The immediate news is a concentrated data push at EURETINA and related meetings: Oculis will deliver late-breaking ACUITY results for Privosegtor and multiple DIAMOND subgroup readouts while also presenting at the Ophthalmology Futures Retina Forum and the Retina Society Annual Congress. In DME, OCS-01, a high-concentration dexamethasone eye drop using the company’s OPTIREACH formulation, is in two Phase 3 trials (DIAMOND-1 and -2) enrolling more than 800 patients with a 52-week BCVA ETDRS primary endpoint. ACUITY’s late-breaker underscores the company’s parallel bet on neuroprotection in a rare, high-unmet-need optic neuropathy where Privosegtor holds FDA and EMA orphan designations.
Strategically, the DME message is about generalizability and positioning. Subgroup analyses by lens status and prior treatment are intended to pre-empt the predictable scrutiny around steroid safety and use-case definition. If OCS-01 can demonstrate vision gains and CST improvements with manageable intraocular pressure signals across phakic and pseudophakic patients—and in both treatment-naïve and previously treated cohorts—it strengthens the case for earlier, topical intervention and combination use later. That is a direct challenge to the injection-first, anti-VEGF-dominated paradigm and aligns with payer interest in less burdensome options and with the FDA’s increasing emphasis on consistency across diverse patient profiles.
Operationally, the DIAMOND regimen—six times daily induction followed by three times daily maintenance—will test adherence at scale, a known weak point for topical therapy in chronic retinal disease. For trial sites and CROs, this raises practical considerations, including adherence monitoring technology, protocolized IOP surveillance, rescue criteria management, and data strategies to correlate dosing fidelity with outcomes. If the pivotal data are positive, real-world implementation will hinge on the same execution levers, potentially shifting more care into community settings and altering visit cadence compared to injection-based care models. For retina practices, a viable topical alternative could redistribute procedure volume and prompt new workflows for IOP monitoring and topical adherence support.
Privosegtor’s ACUITY signal puts neuroprotection back on the agenda in optic neuritis, a space long defined by steroids for inflammation control rather than axonal preservation. The late-breaking slot amplifies visibility, but regulatory risk remains tied to the robustness of functional endpoints, durability of effect, and the translational weight of anatomical measures. Cross-disciplinary site capabilities—in neuro-ophthalmology exams, OCT segmentation for retinal ganglion cell analysis, and standardized low-contrast visual acuity—will be critical in any confirmatory program and may influence site selection and startup timelines.
The next catalytic events are the 52-week readouts from DIAMOND-1 and DIAMOND-2, as well as clarity on Privosegtor’s late-phase design. Watch for subgroup consistency, rescue treatment rates, and the magnitude and manageability of steroid-related IOP signals in OCS-01. For Privosegtor, expect questions on endpoint hierarchy, sample size powering for functional outcomes, and whether regulators will accept current anatomical biomarkers as supportive evidence. Manufacturing scalability for high-concentration topical steroids, adherence enablement in practice, and payer positioning against entrenched anti-VEGF step edits will determine how far these data can move the DME standard of care if the pivotal results hold.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
